Hashmi Hina, Maqbool Amir, Ahmed Saeed, Ahmed Adeel, Sheikh Kulsoom, Ahmed Akhtar
Department of Clinical Oncology, Karachi Institute of Radiotherapy and Nuclear Medicine (KIRAN), Karachi.
Department of Nuclear Medicine, Karachi Institute of Radiotherapy and Nuclear Medicine (KIRAN), Karachi.
J Coll Physicians Surg Pak. 2016 Apr;26(4):302-5.
To evaluate the efficacy of cisplatin-based concurrent chemoradiation in squamous cell carcinoma of cervix and the frequency of acute toxicity.
Case series.
Department of Clinical Oncology, Karachi Institute of Radiotherapy and Nuclear Medicine (KIRAN), Karachi, from September 2010 to September 2011.
Eighty patients with histologically proven squamous cell carcinoma of cervix were included. Patients were treated with concurrent chemoradiation. External beam radiation was delivered with 50 Gy whole pelvis along with 40 mg/m2 weekly cisplatin followed by brachytherapy three insertions of 6.5 Gy each, one week apart. Response to treatment was assessed using response evaluation criteria in solid tumours (RECIST) criteria at 4 weeks after treatment. Acute toxicity of chemoradiation was assessed using common toxicity criteria.
Out of the 80 patients, 8 patients were lost to follow-up. Remaining 72 patients aged 28 - 65 years with mean age of 48.03 ±8.9 years. Forty-eight patients (66%) were in stage II-B, 5 (7%) were in stage III-A, 7 (10%) were in stage III-B, and 12 (17%) were in stage IV-A. Overall response to treatment was 92%, in which 39 (54%) had complete response, and 27 (38%) had partial response while 6 (8%) show progressive disease. About 70% patients had diarrhea, 61.2% patients developed vomiting, 45.8% patients had dermatitis, 43% patients had vaginal mucositis, 40.3% had anemia, 13.9% patients had neutropenia, 27.8% patients had dysuria, and 22.2% patients had proctitis.
Cisplatin-based concurrent chemoradiation is an effective treatment in locally advanced stage of cervical cancer with manageable toxicity.
评估以顺铂为基础的同步放化疗治疗宫颈鳞状细胞癌的疗效及急性毒性发生率。
病例系列研究。
2010年9月至2011年9月，卡拉奇放射治疗与核医学研究所（KIRAN）临床肿瘤学系。
纳入80例经组织学证实的宫颈鳞状细胞癌患者。患者接受同步放化疗。外照射给予全盆腔50 Gy，同时每周给予40 mg/m²顺铂，随后进行近距离放疗，分三次插入，每次6.5 Gy，间隔一周。治疗4周后，采用实体瘤疗效评价标准（RECIST）评估治疗反应。使用常见毒性标准评估放化疗的急性毒性。
80例患者中，8例失访。其余72例患者年龄在28 - 65岁之间，平均年龄为48.03±8.9岁。48例（66%）为II - B期，5例（7%）为III - A期，7例（10%）为III - B期，12例（17%）为IV - A期。总体治疗反应率为92%，其中39例（54%）完全缓解，27例（38%）部分缓解，6例（8%）疾病进展。约70%的患者出现腹泻，61.2%的患者出现呕吐，45.8%的患者出现皮炎，43%的患者出现阴道黏膜炎，40.3%的患者出现贫血，13.9%的患者出现中性粒细胞减少，27.8%的患者出现排尿困难，22.2%的患者出现直肠炎。
以顺铂为基础的同步放化疗是局部晚期宫颈癌的有效治疗方法，毒性可控。
